Brent R. Constantz Ph.D.
Brent R. Constantz, Ph.D. is founder, president, chief executive officer and chief scientist of Norian Corporation in Cupertino, California. Norian Corporation produces Norian SRS=AE (Skeletal Repair System=AE), a cancellous bone cement sets rapidly, allowing immediate fracture stabilization and an early return to function. Brent R. Constantz, Ph.D. is interested in biomineralization and the design of mineralized structures and their function. He has investigated skeletogenetic processes in every animal phylum. Most of his work has been on reef building corals and mammalian bone. In the orthopaedic medical device area, he formed Norian Corporation in 1987, the original player in synthetic bone cement for bone fixation and replacement. He served as President & Chief Executive Officer at Norian, now a subsidiary of Synthes Inc., until coming to Stanford as a Visiting Scholar in 1998. A Consulting Associate Professor teaching Biomineralization (ME/GES 282) and Mineralization of Bone (ME/GES 285) in the Biomechanical Engineering Division, & Geological & Environmental Sciences, Dr. Constantz formed his second medical device company, Corazon Technologies, Inc., in 1999 where he served as President & Chief Executive Officer until 2002. Corazón is a cardiovascular device company based in Menlo Park addressing pathological calcification of the cardiovascular system. Currently, he serves as President & Chief Executive Officer of Skeletal Kinetics LLC, in Cupertino, California. Skeletal Kinetics produces a second generation fracture repair cement that allow patients to return to functional soon after skeletal fractures. Dr. Constantz received a doctorate in Earth Sciences at the University of California at Santa Cruz in 1986 and was a Fulbright Scholar the Weizmann Institute of Science studying biomineralization in 1986 - 1987.EducationDr. Constantz earned a B.A. in aquatic biology and geological sciences from the University of California, Santa Barbara, and an M.S. and Ph. D. in earth sciences from the University of California, Santa Cruz. |
By this ResearcherRelated ContentDuke Bioengineers Use Self-Assembly for Low-Cost Nano Drug DeliveryDuke University nanomedicine researchers may be taking the next step to develop a simple and affordable way to loading targeted nano-doses of cancer drug payloads. Discovery of consistent and reliable self-assembly is a key to success, researchers say.
University of Central Florida Research Finds Nano Clues to Alzheimer's DiseaseNanoresearchers at the University of Central Florida are opening a new avenue in the search for a cure to Alzheimer's disease, having discovered a mechanism that may be responsible for early deterioration of brain function in Alzheimer's victims.
MIT's von Maltzahn Recognized for Nanomedicine ResearchGeoffrey von Maltzahn, 29. of the Massachusetts Institute of Technology is among the winners of 2009 Collegiate Inventors Competition. von Maltzahn won for his advances in nanomedicine to increase the effectiveness of cancer drugs. The competition a program of the National Inventors Hall of Fame sponsored by the Abbott Fund, the non-profit foundation of the global health care company Abbott, and the United States Patent and Trademark Office (USPTO).
|
|||||||||||||||||||||
|
|
||||||||||||||||||||||
Now Online »
CRC Press — 2010 NanoScience and CleanTech catalog